免疫功能受损儿童接种四价HPV疫苗后5年免疫持久性随访
多中心临床试验随访59名5–18岁免疫功能受损儿童,接种三剂四价HPV疫苗后60个月时37人完成随访。cLIA法血清阳转率86.5%–91.9%,IgG法78.4%–94.6%,GMT以cLIA法16型最高373(95%CI:215–649),随访期无严重不良事件。
要点
- 免疫功能受损儿童接种三剂四价HPV疫苗后5年仍具免疫原性。
- cLIA法血清阳转率86.5%–91.9%,IgG法78.4%–94.6%。
- 随访期未报告严重不良事件。
核心结论
- 三剂四价HPV疫苗在免疫功能受损儿童中至接种后5年仍具免疫原性,证据受样本量小限制。
- 需大规模研究确定免疫功能受损儿童的长期保护效果。
研究设计与样本
- 多中心临床试验,随访来自澳大利亚三家儿科医院的5–18岁免疫功能受损儿童,接种三剂四价HPV疫苗,随访至接种后60个月(2007–2016年)。
主要发现
- 59名原始参与者中37人在60个月时完成随访。
- cLIA法血清阳转率:6型86.5%、11型89.2%、16型89.2%、18型91.9%。
- IgG法血清阳转率:6型83.8%、11型83.8%、16型94.6%、18型78.4%。
- cLIA法GMT:11型118(95%CI:79–177)至16型373(95%CI:215–649);IgG法16型最高261(95%CI:143–477),18型最低37(95%CI:21–68)。
- 所有抗体滴度女性低于男性,除16型外差异无统计学意义;随访期未报告严重不良事件。
关键数值与推荐
- 免疫原性主要结局为四价HPV疫苗血清型的血清阳转率和几何平均滴度(GMT)。
临床怎么用
- 支持免疫功能受损儿童按三剂方案接种四价HPV疫苗以维持至5年的免疫原性。
局限性
- 样本量小(59名原始参与者,37人完成60个月随访)。
- 需大规模研究确定长期保护效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human Papillomavirus (HPV) causes significant burden of HPV-related diseases, which are more prevalent in immunosuppressed compared to immunocompetent people. We conducted a multi-centre clinical trial to determine the immunogenicity and reactogenicity of HPV vaccine in immunocompromised children. Here we present the immunogenicity results 5 years post vaccination. METHODS: We followed up immunocompromised children (5-18 years) with a range of specified underlying conditions who were previously recruited from three Australian paediatric hospitals. Participants received three doses of quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11, 16, 18) and were followed up between 2007 and 2016 (60 months post-vaccination). The immunogenicity primary outcome was seroconversion and geometric mean titres (GMT) of the quadrivalent HPV vaccine serotypes in the study. RESULTS: Of the 59 original participants, 37 were followed up at 60 months. The proportion of participants who seroconverted were: 86.5%, 89.2%, 89.2%, 91.9% by competitive Luminex immunoassay (cLIA) and 83.8%, 83.8%, 94.6%, 78.4% by total immunoglobulin G assays (IgG) for serotypes 6, 11, 16 and 18 respectively. GMT values ranged from 118 (95%CI: 79-177) for serotype 11, to 373 (95%CI: 215-649) for serotype 16 by cLIA. For IgG, serotype 16 had the highest GMT of 261 (95%CI: 143-477) and serotype 18 had the lowest value of 37 (95%CI: 21-68). All antibody titres were lower in females compared to males but the difference was not statistically significant except for serotype 16. No serious adverse event was reported during this follow-up period. CONCLUSION: Our evidence, although limited by small numbers, is reassuring that a three dose schedule of HPV vaccine remains immunogenic in immunocompromised children to five years post vaccination. Large scale studies are required to determine long term protection in immunocompromised children. CLINICAL TRIAL REGISTRATION: NCT02263703 (ClinicalTrials.gov).
引用
- MacIntyre CR, Shaw PJ, Mackie FE, et al. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. Vaccine. 2019. PMID: 31402238. doi:10.1016/j.vaccine.2019.07.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。